⌘K
t
On 31 January 2023, e-therapeutics plc announced that, in accordance with FCA Disclosure and Transparency Rules, it has 582,159,332 ordinary shares of 0.1 pence each in issue. None of these shares are held in treasury, making the total number of voting rights in the Company 582,159,332.
| Date | 31 Jan 2023 |
| Time | 07:00:02 |
| Category | Capital structure |
| ID | 2970O |
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
Total Voting Rights
London, UK, 31 January 2023 - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company has 582,159,332 ordinary shares of 0.1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 582,159,332.
The above figure of 582,159,332 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.
For further information, please contact:
|
e-therapeutics plc |
|
|
Ali Mortazavi, CEO James Chandler, VP IR & Communications
|
Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk |
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Broker |
|
|
Matthew Johnson/Harry Davies-Ball (Corporate Finance) |
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data and information resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform. The focus on hepatocytes offers the opportunity to work across a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH"). ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.